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ABSTRACT
Chronic kidney disease (CKD) is increasingly
recognized as a global health problem, and new
and effective strategies are needed for the
management of this condition. Recently, there
has been renewed interest in the relationship
between serum uric acid (SUA) levels and CKD,
and several recent trials have demonstrated a
possible link between SUA and the development
and/or progression of CKD in patients with and
without diabetes. The identification of key urate
transporters such as urate transporter 1 and
glucose transporter 9 has provided not only
insights into the pathophysiology of
hyperuricemia, but also possible links to other
processes, such as glucose homeostasis. The
renewed interest in the role of SUA in CKD
has coincided with the development of sodium
glucose co-transporter 2 inhibitors for the
treatment of diabetes. In addition to
improving glycemic control, these agents,
acting via the kidneys in an
insulin-independent manner, have also been
shown to reduce SUA levels and potentially
improve some measures of renal function. This
review will discuss the role of uric acid in CKD
treatment, and how SUA-lowering therapies
may prevent or delay the progression of CKD.
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INTRODUCTION
Chronic kidney disease (CKD) is a key
determinant of poor health outcomes in major
non-communicable diseases such as
cardiovascular (CV) disease and diabetes, and
it is increasingly recognized as a global public
health problem [1, 2]. The burden of CKD
includes not only progression to end-stage
renal disease (ESRD), but also complications
related to renal impairment and increased risk
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of CV disease [2]. The increased morbidity and
mortality related to CKD may be reduced with
early detection and effective management to
prevent or delay further progression of renal
dysfunction and its associated complications [1,
2].
Interest in the relationship between serum
uric acid (SUA) and CKD has been renewed
recently, due in part to new experimental and
clinical data [3, 4]. The debate continues
regarding whether SUA plays a causal role in
CKD or is simply a marker of renal dysfunction
[3]. Emerging evidence continues to support a
pathogenic role for SUA in CKD [5–9]. Notably,
this renewed interest has coincided with the
development of sodium glucose co-transporter
2 (SGLT2) inhibitors for type 2 diabetes mellitus
(T2DM); these agents, acting via the kidneys in
an insulin-independent manner, reduce SUA
and potentially improve renal outcomes
[10–13]. In this review, we will discuss the
currently available evidence on the relationship
between SUA and CKD, and how the uric
acid-lowering effects of SGLT2 inhibitors may
contribute to renoprotection. This article is
based on previously conducted studies, and
does not involve any new studies of human or
animal subjects performed by the author.
URIC ACID AND HYPERURICEMIA
Uric acid is a weak organic acid that under
physiologic conditions exists mainly as
monosodium urate [14]; therefore, uric acid
and urate, although chemically different, are
generally interchangeable terms. In higher
primates, uric acid is the end product of the
metabolism of unwanted purine nucleotides [4,
10, 15]. Unlike other mammals, higher primates
lack the enzyme uricase that converts uric acid
to allantoin [15–17]. Beneficial effects of uric
acid, such as its ability to scavenge harmful
radicals, may have been evolutionarily
advantageous [15, 16]. However, increased
SUA levels can lead to urate crystallization and
associated complications, such as kidney stones
and gout. There is also increasing evidence that
increased SUA levels may negatively affect CV
and renal health in a crystal-independent
manner [18].
About two-thirds of uric acid is produced
endogenously, primarily in the liver, muscle,
and intestine, and one-third is derived from
dietary sources, including fructose, alcohol, and
purine-rich foods like certain meats and seafood
[4]. Uric acid is produced from fructose via an
endogenous pathway as well as from dietary
sources (e.g., corn syrup), and a high fructose
intake can cause intracellular adenosine
triphosphate depletion and nucleotide
turnover, with uric acid formation [19]. In
diabetes, fructose is generated endogenously
via the polyol pathway; blocking the
metabolism of fructose in a diabetic mouse
model has been found to mitigate the
development of tubulointerstitial injury
through blocking the production of tubular
uric acid [20].
Overall, the SUA level is determined
primarily by a balance of uric acid generation,
reabsorption, and excretion in the kidney, but it
can also be influenced by other factors, like
dietary purine intake, hydration status, and use
of diuretics [4, 15]. Volume depletion will
reduce uric acid excretion independently of
urine flow [21], while a comparison of
mannitol- and glucose-associated osmotic
diuresis showed that, for each osmolar unit,
glucosuric diuresis had a threefold greater
uricosuric effect [22].
Uric acid is excreted primarily via the
kidneys; therefore, the kidneys play an
important role in regulating SUA levels [4, 23].
In the kidneys, urate reabsorption and secretion
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are regulated by multiple urate transporters. For
example, urate transporter 1 (URAT1) is
expressed in the apical membrane of proximal
tubule cells and is responsible for urate
reabsorption [15, 24]. In addition, two
isoforms of the urate transporter SLC2A9
(glucose transporter 9 [GLUT9]) are known,
one expressed at the baso-lateral side of the
proximal tubule and the other on the apical
membranes in the collecting duct. Normally, no
glucose will reach the collecting ducts, but in
diabetes (and especially with SGLT2 inhibition)
large amounts of glucose can be excreted:
GLUT9 is now exchanging glucose and
fructose for uric acid, and therefore plays an
important role in regulating urate homeostasis
[23, 25–29]. Only a small fraction of uric acid
(8–10%) is excreted (net urinary urate excretion
is 250–750 mg/day), as about 90% of filtered
urate is reabsorbed [4]. Obesity, insulin
resistance, hypertension, and diuretic use have
been associated with increased urate
reabsorption in renal tubules and
hyperuricemia [4]. It is currently not known
how tubuloglomerular feedback or
fructose-induced uric acid formation can affect
uricosuria in the setting of SGLT2 inhibition.
The definition of hyperuricemia in adults is
not universally agreed upon, but commonly
used thresholds are in the range of 6–7 mg/dL
(350–400 lM/L), and are usually higher for men
than for women [23]. The presence of
hyperuricemia has been associated with a
number of disorders including CV and renal
disease, metabolic syndrome, diabetes, and
hypertension [30]. In patients with T2DM,
hyperuricemia is associated with an increased
risk of developing gout, kidney stones, vascular
complications [31, 32], and death [32].
Establishing the exact relationship between
SUA level and diabetes has been complicated by
the fact that both hypouricemia and
hyperuricemia have been linked to diabetes
[33]. SUA levels may be low in patients with
recently diagnosed diabetes due to increased
urate excretion [34]. Hyperuricemia, on the
other hand, has been associated with the
development of diabetes, especially in the
context of insulin resistance and impaired
glucose tolerance [35]. In a large
population-based study, increased SUA levels
were shown to be an independent risk factor for
developing T2DM, and one-quarter of diabetes
cases could be attributed to high SUA levels
[36]. These findings may have a strong public
health impact, as lowering SUA may decrease
the incidence of diabetes, if the relationship is
causal [37].
CHRONIC KIDNEY DISEASE
CKD is defined as abnormalities of kidney
structure or function that persist for more
than 3 months with health implications [37,
38]. Abnormalities include decreased
glomerular filtration rate (GFR; \60 mL/min/
1.73 m2) or evidence of one or more markers of
kidney damage (albuminuria, urine sediment
abnormalities, electrolyte abnormalities,
abnormalities detected by histology or
imaging, or history of kidney transplantation
[37]). CKD is becoming increasingly recognized
as a worldwide public health problem that may
be more common in developing countries and
in disadvantaged and minority populations [1].
In the USA, CKD is present in over 13% of the
population, making it more prevalent than
diabetes [38, 39]. Using an updated Kidney
Disease: Improving Global Outcomes (KDIGO)
classification system for CKD to include the
level of both renal function and urinary
albumin excretion, recent estimates suggest
that the prevalence of CKD among patients
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with diabetes is 43.5%, and the prevalence of
mildly decreased renal function or worse
[estimated GFR (eGFR)\60 mL/min/1.73 m2] is
22.0% [40]. Diabetic kidney disease is the single
strongest predictor of mortality in patients with
diabetes [41, 42]. Furthermore, CKD is
associated with an eight- to tenfold increase in
CV mortality, and its presence is a negative risk
factor in patients with diabetes and
hypertension [1]. In developed countries like
the USA, diabetic kidney disease is the leading
cause of ESRD [41].
Prognosis is determined primarily by GFR
and albuminuria category (albumin excretion
rate \30 [A1], 30–300 [A2], or [300 [A3] mg/
24 h for normal, microalbuminuria, or
macroalbuminuria [clinical proteinuria],
respectively) [43], but other factors, such as
the cause of CKD and presence of comorbidities,
may also be taken into account. Progression of
CKD, as defined by a decline in category (e.g.,
from CKD stage 3 to 4) or a loss of 5 mL eGFR or
more per year, can potentially lead to ESRD. It
has been suggested that early detection and
management of CKD, when patients are
typically seen by general internists, can slow
or prevent progression of the disease using
simple and relatively inexpensive
interventions, including control of blood
pressure and, in diabetes, blood glucose level
[1, 44]. However, while glycemic control has
been shown to reduce the initial development
of micro- and macroalbuminuria, there are
limited data on its effects on GFR [45, 46].
Control of CV risk factors, such as
hyperlipidemia, plays also an important role
in the management of patients with diabetic
kidney disease [38]. Despite evidence of
significant reductions in CV events with statin
therapy in patients with and without
albuminuria, no significant effect on slowing
CKD progression was found with statin use [45,
47, 48]; these findings highlight the need for
more effective strategies for managing CKD.
RELATIONSHIP BETWEEN
HYPERURICEMIA AND CKD
SUA levels are usually increased in patients with
CKD, but whether SUA plays a causal role in
CKD remains a topic of debate [3, 4]. A recent
renal biopsy study of 167 Japanese patients with
CKD (eGFR \60 mL/min/1.73 m2) found that,
after adjusting for age, sex, hypertension,
diabetes, and eGFR, an SUA level above
7.2 mg/dL was associated with renal arterial
wall thickening and hyalinosis consistent with
renal arteriolopathy [49]. The suggestion that
hyperuricemia is a risk factor for CKD is
supported by many studies. Preclinical data
suggest that hyperuricemia induces renal
injury through multiple crystal-independent
mechanisms involving renal vasoconstriction
mediated by endothelial dysfunction,
inflammation, and activation of the
renin–angiotensin system (Fig. 1) [8, 17, 18,
50–53]. Hyperuricemia has also been associated
with afferent renal arteriolopathy,
tubulointerstitial fibrosis, and renal
inflammation [54].
Data from most epidemiological studies
suggest that uric acid is a major independent
risk factor for the development and progression
of renal disease in patients both with [9, 55–57]
and without diabetes [56, 58–68]. In a recent
meta-analysis of 13 observational trials
involving over 190,000 patients [56], the
presence of hyperuricemia was an independent
predictor of new-onset CKD development. The
effect was seen in subsets of patients with and
without diabetes, and the magnitude of the
effect was comparable in both subsets. Possibly
reflecting dietary differences, this effect was
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more pronounced in Western populations than
in Asian populations [56]. Notably, in patients
with increased SUA levels, the risk of developing
new-onset CKD increased as the duration of
follow-up increased, suggesting that
hyperuricemia may play a role in the
long-term progression of chronic renal
dysfunction [56]. In a recent cross-sectional
study enrolling 3212 Chinese patients with
T2DM, the prevalence of diabetic kidney
disease was significantly elevated in
hyperuricemia subjects and increased with
increasing uric acid levels [55]. The presence of
a mutation in the urate transporter GLUT9
strongly predicted progression of CKD in a
cohort of 755 patients with CKD [69]. Lastly,
in a study of 4233 women, increased SUA
during pregnancy was associated with a higher
risk of subsequent hospitalization for significant
atherosclerotic-related events, including renal
failure, diabetic ketoacidosis, hypertensive
crisis, and CV events [70].
Some epidemiological studies, however,
have reported no significant relationship
between hyperuricemia and progression of
kidney disease and development of kidney
failure [71, 72]. In a prospective analysis of the
Mild to Moderate Kidney Disease study, 177
patients with non-diabetic primary CKD and
various stages of renal impairment were
Fig. 1 Potential mechanisms of uric acid-induced kidney
disease [4]. COX-2 Cyclooxygenase-2, ECM extracellular
matrix, EMT epithelial-to-mesenchymal transition, NO
nitric oxide, RAS renin–angiotensin system, VEC vascular
endothelial cells, VSMC vascular smooth muscle cells.
Reprinted from Seminars in Nephrology, Vol. 32, Issue 5.
Kang DH, Chen W, Uric acid and chronic kidney disease:
new understanding of an old problem. pp. 447–52.
Copyright 2011, with permission from Elsevier
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followed for 7 years [71]. Increased SUA levels
predicted CKD progression only when patients
receiving uric acid-lowering drugs were
excluded from the analysis. After adjusting for
baseline GFR and proteinuria, hyperuricemia
was no longer an independent predictor of CKD
progression [71]. Similarly, in the Modification
of Diet in Renal Disease study, 838 patients with
stage 3–4 CKD were followed for median of
10 years [72]. In continuous analyses, each
1 mg/dL increase in SUA level was associated
with an increased risk of all-cause mortality and
CV disease-related mortality, but not with
progression to kidney failure [72].
Diabetes
In patients with diabetes, a multifactorial
treatment approach with angiotensin-
converting enzyme (ACE) inhibitors or
angiotensin receptor blockers (ARBs) is needed
to control hypertension, i.e., reducing blood
pressure below 140/90 mmHg, and to lower
albuminuria. Tight glucose control and
correction of hyperlipidemia have been shown
to reduce CV risks, but currently no data exist to
show that such interventions can slow down
the progression of CKD [50, 73]. In patients
with type 1 diabetes mellitus, elevated SUA
levels at baseline were shown to predict the
development of CKD in several trials [5–7, 57].
A recent multiple regression analysis performed
on 1108 patients with type 1 diabetes identified
SUA as the third most important risk factor after
tumor necrosis factor receptor 1 and
albuminuria, associated with early progressive
renal decline [74]. Similar results have been
reported in patients with T2DM. For example,
in a study of 1449 patients with T2DM, normal
kidney function, and no proteinuria, subjects
were followed for 5 years to assess the
occurrence of new-onset CKD [9]. During the
5-year period, the cumulative incidence of CKD
was significantly higher in patients with
baseline hyperuricemia ([7.0 mg/dL)
compared with those without hyperuricemia
(29.5% vs. 11.4%). A multivariate analysis in
this population of patients with T2DM
confirmed that hyperuricemia, together with
older age, use of antihypertensive drugs, and
lower eGFR and higher albuminuria at baseline,
was an independent risk factor for the
development of CKD [9].
IgA Nephropathy
IgA nephropathy (IgAN) is the most common
type of primary glomerular disease
characterized by variable tubulointerstitial
lesions, and it can progress to ESRD over time
[75]. In patients with IgAN, SUA levels have
been shown to correlate with renal damage [76,
77] and progression of IgAN [58, 78, 79]. In a
recent study of 93 patients with IgAN, baseline
SUA levels significantly predicted the change in
eGFR over a 6-month period after adjusting for
multiple factors, including baseline GFR and
albumin level [58]. In a long-term study (mean
follow-up 5 years) of 348 consecutive cases of
IgAN, patients with high SUA levels at baseline
were significantly more likely to experience a
decline in GFR (41% vs. 16%) and develop ESRD
(65% vs. 35%) compared with patients with
SUA levels within the normal range [78].
Acute Kidney Injury
Lastly, little is known about the relationship
between SUA and acute kidney injury (AKI).
Data from Atherosclerosis Risk in Communities,
a population-based study of over 11,000
participants followed for an average of
12 years, indicated that increased plasma urate
([5.0 mg/dL) was independently associated
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with the risk of hospitalization for AKI [80]. For
each 1 mg/dL increase in plasma urate beyond
5.0 mg/dL, the risk of AKI increased 16%.
However, a causal role of urate in AKI could
not be established.
EFFECTS OF LOWERING SUA LEVELS
SUA levels are an important risk factor for
progression of renal dysfunction,
hypertension, and lifestyle-related diseases
such as metabolic syndrome or T2DM.
Lowering SUA levels may represent a new
therapeutic approach, but large clinical trials
are warranted to evaluate the associated benefits
and risks before implementation in clinical
practice.
Allopurinol
Several small studies have explored the impact
of treatment with the xanthine oxidase
inhibitor allopurinol on renal outcomes
[81–85]. Recent meta-analyses have produced
variable results. In an analysis of randomized
trials of patients with or without CKD at
baseline, uric acid-lowering therapy with
allopurinol had no effect on GFR compared
with controls in five trials (n = 346) but
abrogated increases in serum creatinine in
three trials (n = 130) [85, 86]. In a separate
analysis of 19 randomized trials involving a
total of 992 patients with stage 3–5 CKD,
treatment with allopurinol was associated with
significant reductions in SUA levels and blood
pressure and more favorable eGFR compared
with controls [87]. Both meta-analyses reported
significant heterogeneity among the trials of
allopurinol in terms of design, duration of
follow-up, and comparators used. It has been
suggested that the potential renoprotective
effect observed in one study of allopurinol
may have been caused by lowering SUA levels
from slightly above to slightly below the uric
acid saturation point (6.8 mg/dL); mean SUA
levels over the 7-year observation period were
7.2 mg/dL in the control group and 6.5 mg/dL
in the allopurinol-treated group. Reducing the
SUA level as low as possible may be less
important than simply maintaining the level
below the saturation point, in terms of
preventing renal damage [84, 85].
Interpretation of results obtained with
allopurinol can also be complicated by a
secondary effect related to xanthine oxidase.
Xanthine oxidase, which is inhibited by
allopurinol, produces reactive oxygen species
(ROS); inhibition of this ROS formation with
allopurinol may have beneficial effects
unrelated to SUA levels [4, 54, 87]. Two
ongoing trials sponsored by the US
government are evaluating the effects of
allopurinol on the progression of IgAN [88]
and diabetic nephropathy in patients with type
1 diabetes mellitus [89, 90].
Febuxostat and Topiroxostat
Febuxostat is a non-purine selective inhibitor of
xanthine oxidase approved by the US FDA for
the treatment of adult hyperuricemia with gout
(not for hyperuricemia alone), and can be used
in stage 3 CKD (eGFR 30–60 mL/min/1.73 m2).
A 108-week prospective, double-blind,
placebo-controlled study (FEATHER; UMIN
identifier, UMIN000008343) is currently
ongoing, investigating the effect of febuxostat
on eGFR in 400 adult Japanese patients with
stage 3 CKD and hyperuricemia (SUA
7.1–10.0 mg/dL) without gouty arthritis [91].
Topiroxostat is another selective xanthine
oxidase inhibitor, approved for use in Japan. A
recent 22-week double-blind study in 123
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patients with stage 3 CKD and hyperuricemia
with or without gout showed that treatment
with topiroxostat significantly reduced SUA by
about 45% and lowered the albumin to
creatinine ratio by almost 30%, compared with
placebo [92].
Losartan
Losartan is an ARB that has renoprotective
effects in patients with diabetic nephropathy
[93]. This effect is attributed primarily to its
ability to reduce blood pressure and
proteinuria [93], but evidence indicates that,
unlike other ARBs, losartan also reduces SUA
levels [94], possibly by inhibition of URAT1,
leading to reduced urate reabsorption in the
proximal tubule [95]. To determine the effect
of SUA reduction on renal outcomes in
patients with T2DM and nephropathy treated
with losartan, a post hoc analysis was
conducted using data from the Reduction of
Endpoints in Non-Insulin-Dependent Diabetes
Mellitus with the Angiotensin II Antagonist
Losartan Trial (ClinicalTrials.gov identifier,
NCT00308347) [96]. In 1342 patients,
losartan treatment significantly reduced SUA
levels over a 6-month period. Moreover, for
every 0.5 mg/dL decrement in SUA, the risk of
adverse renal outcomes (a doubling of serum
creatinine or development of ESRD) decreased
by 6% [96]. Excluding the effects of SUA on
renal outcomes reduced the renoprotective
effect of losartan from 22% to 17%,
suggesting that the SUA-lowering effect of
losartan accounts for approximately one-fifth
of the agent’s renoprotective effects [96].
Results of this post hoc analysis provide
evidence that strategies to reduce SUA levels
may reduce renal risk.
SGLT2 Inhibitors
The kidney plays a key role in glucose
homeostasis by contributing to endogenous
glucose production via gluconeogenesis and by
reabsorbing filtered glucose [97]. SGLT2 is a
high-capacity, low-affinity glucose transporter
that is found primarily in the proximal tubule
of the kidney and is responsible for 90% of
glucose reabsorption [98]. Inhibition of SGLT2
increases urinary glucose excretion, thereby
improving glycemic control in an
insulin-independent manner in patients with
T2DM [99]. As a class, SGLT2 inhibitors have
shown multiple beneficial effects in patients
with T2DM, including reduction in HbA1C,
decreased blood pressure, and weight loss
[11–13, 98, 99]. They may also have some
beneficial renal-related effects, including a
reduction in intraglomerular pressure and
amelioration of albuminuria [100, 101]. In
addition, SGLT2 inhibitors also reduce SUA
levels, possibly through mediating the GLUT9
urate transporter via induction of glycosuria:
higher levels of glucose in the urine due to
SGLT2 inhibition result in a higher level of
exchange of uric acid across the apical
membrane of tubular cells, so more uric acid is
released from blood into the urine, ultimately
reducing SUA levels [10, 102, 103]. In a pooled
analysis of data from four phase 3 trials,
canagliflozin was shown to reduce SUA levels
compared with placebo [10]. In a subgroup with
hyperuricemia at baseline, 20–30% of patients
with hyperuricemia achieved normal SUA levels
after 26 weeks of treatment with canagliflozin
[10]. Similarly, in a meta-analysis of small,
randomized, placebo-controlled trials,
treatment with dapagliflozin at doses B20 mg
significantly reduced SUA levels [13]. Results
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from individual phase 2 trials of the SGLT2
inhibitor empagliflozin have reported
reductions in SUA [11, 12]. The uricosuric
effect seen in phase 3 trials of all three
FDA-approved SGLT2 inhibitors has not been
associated with an increase in uric acid
nephrolithiasis.
The beneficial effects of SGLT2 inhibition on
renal parameters must be weighed against
potential side effects [98]. As a class, SGLT2
inhibitors have been associated with an
increased risk of genitourinary infections, both
bacterial and fungal [11–13, 104]. For example,
in clinical trials, canagliflozin was associated
with increased risk of genital mycotic infections
as well as events related to osmotic diuresis
[104]. Renal-related adverse events were
uncommon. Small, transient reductions in
eGFR have been observed with SGLT2
inhibitors during the initial weeks of
treatment [12, 104], but longer-term studies
(104 weeks) have confirmed that eGFR remains
stable after this initial reduction [101, 105].
Since the efficacy of SGLT2 inhibitors is
dependent on renal function, it is not
surprising that the HbA1C-lowering effects of
SGLT2 inhibitors are reduced in patients with
renal impairment [106–108]. In the USA,
initiation of available SGLT2 inhibitors
requires an eGFR [45 mL/min/1.73 m2 for
empagliflozin and canagliflozin (100 mg), and
[60 mL/min/1.73 m2 for dapagliflozin.
Ongoing trials may provide further insight
into the effects of SGLT2 inhibitors on SUA
and renal outcomes. The CREDENCE trial
(ClinicalTrials.gov identifier, NCT02065791),
for example, is a phase 3 trial evaluating
canagliflozin in patients with T2DM, stage 2 or
3 CKD (eGFR 60–89 and 45–59 mL/min/
1.73 m2, respectively), and macroalbuminuria
(albumin excretion [300 mg/24 h) [109]. The
trial will assess whether canagliflozin has renal
and vascular protective effects in this
population. The ongoing phase 4 CANVAS-R
trial (ClinicalTrials.gov identifier,
NCT01989754) [110] will also study the effects
of canagliflozin on renal endpoints.
CONCLUSIONS
The burden of CKD is increasingly recognized
as a global health problem, underscoring the
need for new and effective
disease-management strategies. Renewed
interest in the relationship between uric acid
and CKD has led to new data that, on the
whole, suggest that SUA may be a modifiable
risk factor for CKD. Ongoing research
continues to explore the exact relationship
between hyperuricemia and CKD, and how
SUA-lowering therapies may influence renal
outcomes. Preliminary data suggest that
SGLT2 inhibitors can reduce SUA levels,
which may in turn contribute to a potential
renoprotective effect. Ongoing clinical studies
are prospectively evaluating the effect of SLGT2
inhibitors on SUA levels and renal parameters
and outcomes in patients with CKD.
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